BACKGROUND AND AIMS: Pharmacokinetic data for proton pump inhibitors (PPIs), acid-suppression drugs commonly prescribed to children, are lacking for obese children who are at greatest risk for acid-related disease. In a recent multi-center investigation, we demonstrated decreased, total body weight adjusted, apparent clearance (CL/F) of the PPI pantoprazole for obese children compared with their non-obese peers. Subsequently, we developed a population-based pharmacokinetic (PopPK) model to characterize pantoprazole disposition and evaluated appropriate pantoprazole dosing strategies for obese pediatric patients, using simulation. METHODS: Pharmacokinetic data from the only prospective study of PPIs in obese children (aged 6-17 years; n = 40) included 273 pantoprazole and 256 pantoprazole-sulfone plasma concentrations, after single oral-dose administration, and were used for pantoprazole model development and covariate analysis (NONMEM®). Model evaluation was performed via bootstrapping and predictive checks, and the final model was applied to simulate systemic pantoprazole exposures for common dosing scenarios. RESULTS: A two-compartment PopPK model, which included CYP2C19 genotype and total body weight, provided the best fit. Resultant, typical, weight-normalized pantoprazole parameter estimates were different than previously reported for children or adults, with significantly reduced pantoprazole CL/F for obese children. Of the dosing scenarios evaluated, the weight-tiered approach, approved by the US Food and Drug Administration, achieved pantoprazole exposures [area under the curve (AUC0-∞)] within ranges previously reported as therapeutic, without over- or under-prediction for obese children. CONCLUSIONS: Our data argue against empiric dose escalation of PPIs for obese children and support current FDA-approved pediatric weight-tiered dosing for pantoprazole; however, 3- to 5-fold inter-individual variability in pantoprazole AUC0-∞ remained using this dosing approach.
BACKGROUND AND AIMS: Pharmacokinetic data for proton pump inhibitors (PPIs), acid-suppression drugs commonly prescribed to children, are lacking for obese children who are at greatest risk for acid-related disease. In a recent multi-center investigation, we demonstrated decreased, total body weight adjusted, apparent clearance (CL/F) of the PPI pantoprazole for obese children compared with their non-obese peers. Subsequently, we developed a population-based pharmacokinetic (PopPK) model to characterize pantoprazole disposition and evaluated appropriate pantoprazole dosing strategies for obese pediatric patients, using simulation. METHODS: Pharmacokinetic data from the only prospective study of PPIs in obese children (aged 6-17 years; n = 40) included 273 pantoprazole and 256 pantoprazole-sulfone plasma concentrations, after single oral-dose administration, and were used for pantoprazole model development and covariate analysis (NONMEM®). Model evaluation was performed via bootstrapping and predictive checks, and the final model was applied to simulate systemic pantoprazole exposures for common dosing scenarios. RESULTS: A two-compartment PopPK model, which included CYP2C19 genotype and total body weight, provided the best fit. Resultant, typical, weight-normalized pantoprazole parameter estimates were different than previously reported for children or adults, with significantly reduced pantoprazole CL/F for obese children. Of the dosing scenarios evaluated, the weight-tiered approach, approved by the US Food and Drug Administration, achieved pantoprazole exposures [area under the curve (AUC0-∞)] within ranges previously reported as therapeutic, without over- or under-prediction for obese children. CONCLUSIONS: Our data argue against empiric dose escalation of PPIs for obese children and support current FDA-approved pediatric weight-tiered dosing for pantoprazole; however, 3- to 5-fold inter-individual variability in pantoprazole AUC0-∞ remained using this dosing approach.
Authors: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Comput Methods Programs Biomed Date: 2010-06-02 Impact factor: 5.428
Authors: Catherijne A J Knibbe; Margreke J E Brill; Anne van Rongen; Jeroen Diepstraten; Piet Hein van der Graaf; Meindert Danhof Journal: Annu Rev Pharmacol Toxicol Date: 2014-10-17 Impact factor: 13.820
Authors: Gregory L Kearns; Jeffrey Blumer; Stephen Schexnayder; Laura P James; Kim G Adcock; Michael D Reed; James F Daniel; Andrea Gaedigk; Jeffrey Paul Journal: J Clin Pharmacol Date: 2008-07-29 Impact factor: 3.126
Authors: Ron J Keizer; Robert S Jansen; Hilde Rosing; Bas Thijssen; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Pharmacol Res Perspect Date: 2015-03-25
Authors: Kathryn E Kyler; Jonathan Wagner; Chelsea Hosey-Cojocari; Kevin Watt; Valentina Shakhnovich Journal: Paediatr Drugs Date: 2019-10 Impact factor: 3.022
Authors: Keith Feldman; Gregory L Kearns; Robin E Pearce; Susan M Abdel-Rahman; James Steven Leeder; Alec Friesen; Vincent S Staggs; Andrea Gaedigk; Jaylene Weigel; Valentina Shakhnovich Journal: Clin Transl Sci Date: 2022-02-14 Impact factor: 4.438
Authors: Timothy A Roberts; Jennifer A Wagner; Tracy Sandritter; Benjamin T Black; Andrea Gaedigk; Stephani L Stancil Journal: Clin Transl Sci Date: 2020-10-15 Impact factor: 4.689
Authors: John J Lima; Cameron D Thomas; Julia Barbarino; Zeruesenay Desta; Sara L Van Driest; Nihal El Rouby; Julie A Johnson; Larisa H Cavallari; Valentina Shakhnovich; David L Thacker; Stuart A Scott; Matthias Schwab; Chakradhara Rao S Uppugunduri; Christine M Formea; James P Franciosi; Katrin Sangkuhl; Andrea Gaedigk; Teri E Klein; Roseann S Gammal; Takahisa Furuta Journal: Clin Pharmacol Ther Date: 2020-09-20 Impact factor: 6.903